Year Published
- (-) Remove 2008 filter 2008
- 2009 (0)
- (-) Remove 2010 filter 2010
- (-) Remove 2011 filter 2011
- 2012 (0)
- 2013 (0)
- (-) Remove 2014 filter 2014
- 2015 (0)
- 2016 (1) Apply 2016 filter
- (-) Remove 2017 filter 2017
- 2018 (1) Apply 2018 filter
- 2019 (0)
- 2020 (0)
- 2021 (0)
Research Topics
Populations
- Countries/Governments (0)
- Rural Populations (0)
- Smallholder Farmers (0)
- Women (0)
Types of Research
- Data Analysis (1) Apply Data Analysis filter
- (-) Remove Literature Review filter Literature Review
- (-) Remove Portfolio Review filter Portfolio Review
- Research Brief (0)
Geography
- East Africa Region and Selected Countries (2) Apply East Africa Region and Selected Countries filter
- (-) Remove Global filter Global
- South Asia Region and Selected Countries (4) Apply South Asia Region and Selected Countries filter
- Southern Africa Region and Selected Countries (0)
- Sub-Saharan Africa (9) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (0)
Dataset
- ASTI (0)
- FAOSTAT (0)
- Farmer First (0)
- LSMS & LSMS-ISA (0)
- Other Datasets (0)
Current search
- (-) Remove 2010 filter 2010
- (-) Remove 2008 filter 2008
- (-) Remove Agricultural Productivity, Yield, & Constraints filter Agricultural Productivity, Yield, & Constraints
- (-) Remove 2011 filter 2011
- (-) Remove 2017 filter 2017
- (-) Remove Literature Review filter Literature Review
- (-) Remove 2014 filter 2014
- (-) Remove Research & Development filter Research & Development
- (-) Remove Global filter Global
- (-) Remove Portfolio Review filter Portfolio Review
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.